5α-Hydroxy-laxogenin,
does it really help with Increased muscle mass and strength as a 'natural anabolic'?
research shows5α-Hydroxy-laxogenin is rated ? because no human efficacy trial assessing muscle mass or strength could be identified. The located literature consists of marketed-product analyses, cellular androgen-receptor assays, cultured-muscle work, and animal studies rather than clinical efficacy trials. FDA determined that the substance is not a lawful dietary ingredient and is not GRAS for the intended use, but that regulatory finding concerns legality and composition rather than a trial disproving efficacy. Human safety is also unestablished, and label inaccuracies and undeclared drugs have been reported, so efficacy, safety, and product variability are kept separate.
ads claimMarketing portrays it as plant-derived, nonhormonal, and a side-effect-free steroid alternative. In reality, natural occurrence has not been demonstrated, and cellular signals are being extrapolated simultaneously to human muscle gain and safety.
Useful facts when choosing a product
- 5α-Hydroxy-laxogenin is labeled in muscle-building supplements as a natural anabolic or as laxogenin, although it is a synthetic spirostane-type substance with no demonstrated isolation from a natural source.
- In 2022 warning letters, FDA determined that it was not a dietary ingredient and was neither an approved food additive nor GRAS for the intended use.
- Analyses of marketed products found discrepancies between labels and measured contents as well as undeclared drugs, stimulants, or designer steroids, making actual exposure uncertain from the label alone.
- Because human efficacy and safety trials are absent, no clinically validated dose, duration, contraindication, or interaction profile has been established.
What the research actually shows
Cohen 2020 analyzed four purchasable products listed in the NIH label database as containing 5α-hydroxy-laxogenin and found major discrepancies between labeled and measured ingredients plus undeclared drugs. Keiler 2022 reported a high-concentration androgen-receptor signal in cellular assays, which was not a human efficacy experiment. Derwand 2025 found no anabolic or androgenic effect on prostate, seminal vesicle, levator ani, or skeletal muscle after two weeks of subcutaneous exposure in orchiectomized rats. FDA warning letters in 2022 concluded that the substance did not meet the dietary-ingredient definition and was neither an approved food additive nor GRAS for the intended use. None of the located sources compared human muscle mass or strength.
Why this is classified as ?
The absence of any human muscle-mass or strength efficacy trial requires ? with a null score. Cellular and animal studies are not human efficacy literature, and an FDA warning is a regulatory composition finding rather than an efficacy trial. Unestablished safety, liver-injury reports involving the broader bodybuilding-supplement class, and product mislabeling are separate safety issues and do not establish single-ingredient hepatotoxicity from 5α-hydroxy-laxogenin.
Counterpoint. Training and adequate protein intake remain the validated basis for improving muscle and strength. Use of this ingredient raises concerns about unknown exposure, doping, and liver injury before any credible expectation of benefit.
Rejudgment record. New verdict — Applied ? for absent human efficacy literature because no human muscle-mass or strength trial was found and all located work was product analysis, cellular, or animal research; regulatory warnings and product variability were separated from efficacy grading
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased human muscle mass and strength | ? | No human efficacy trial measuring these endpoints was identified. |
| A safe alternative to anabolic steroids | ? | Both comparative clinical efficacy and human safety data are absent. |
| Established human safety | ? | No single-ingredient human safety trial exists, and adulteration makes actual exposure uncertain. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Cohen PA et al. 2020 | Case series with laboratory analysis of marketed supplements | 4 | Academic study; funding details reported in the article | Detected ingredients and amounts versus product labels | Found label discrepancies and undeclared drugs or ingredients; muscle mass and strength were not measured. | Key product-variability evidence; not a human efficacy trial |
| Keiler AM et al. 2022 | Yeast and human prostate-cell androgen-receptor bioassays | Academic preclinical research | In-vitro androgen-receptor activity | A receptor-activity signal appeared at high concentrations, but human muscle mass and strength were not assessed. | Mechanistic hypothesis; not a human efficacy trial | |
| Derwand R et al. 2025 | Preclinical orchiectomized-rat experiment | Academic preclinical research | Weights of androgen target tissues, levator ani, and skeletal muscles | No anabolic or androgenic effect was observed after two weeks of administration. | Negative preclinical signal; cannot replace a human verdict |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] 5α-Hydroxy-laxogenin x increased muscle mass and strength — Evidence Grade ?. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/5-alpha-hydroxy-laxogenin-muscle-mass-strength/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.